An Inflection Point In Anheuser Busch Inbev Is 'Imminent'

0 Comments 5 view(s)

CLSA reiterated its Outperform rating on Anheuser Busch Inbev SA (ADR) (NYSE: BUD) and retained the 12-month price objective of $145.00.

Analysts, led by Caroline Levy, see an imminent inflection point, indicating the shift in rapidly-growing high-end brands.

Latest Ratings for BUD

Date Firm Action From To
Aug 2016 Susquehanna Downgrades Positive Neutral
May 2016 Bernstein Maintains Market Perform
Apr 2016 Societe Generale Downgrades Hold Buy

View More Analyst Ratings for BUD

View the Latest Analyst Ratings

Powered by WPeMatico